Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Sunandana Chandra

Melanoma · NU

View

Dr. Kathleen Cooney

GU Oncology · Duke

View

Dr. Rebecca Shatsky

Breast Oncology · UCSD

View

Dr. Robert Bast

Breast Oncology · MD Anderson Cancer Center

View

Dr. Julia Close

General Oncology · UF

View

Dr. Sara Tolaney

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Allison Fitzgerald

General Oncology · Dana-Farber Cancer Institute

View

Dr. Jason Mouabbi

Breast Oncology · MD Anderson Cancer Center

View

Dr. Rebecca Miksad

GI Oncology · BMC

View

Dr. Lee Scheinbart

General Oncology · Burrell College of Osteopathic Medicine

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    DDDr. Diwakar Davar
    Leading Voice

    Dr. Diwakar Davar

    Medical Oncology · Melanoma Oncology
    UPMC Mercy Hospital
    diwakar
    Pittsburgh, PA, USA

    Research

    Radiomic analysis of patient and interorgan heterogeneity in response to immunotherapies and BRAF-targeted therapy in metastatic melanoma

    2025

    Via Journal for Immunotherapy of Cancer

    Research

    Zinc availability in the tumor microenvironment dictates anti-PD1 response in tumors via increased macrophage phagocytosis

    2025

    Via bioRxiv

    Research

    There and back again: PD-L1 Positivity as a Biomarker for Immune Checkpoint Blockade in Urothelial Carcinoma

    2025

    Via Cancer Immunology Research

    Research

    Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma

    2025

    Via Journal of Clinical Oncology

    Research

    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer: AMBER Part 2B

    2025

    Via Clinical Cancer Research

    Research

    Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Melanoma: AMBER Cohorts 1c, 1e, and 2A

    2025

    Via Clinical Cancer Research

    Research

    Therapeutic potential of targeting LAG-3 in cancer

    2025

    Via Journal for Immunotherapy of Cancer

    Research

    Exercise-induced microbiota metabolite enhances CD8 T cell antitumor immunity promoting immunotherapy efficacy

    2025

    Via Cell

    Research

    Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption

    2025

    Via Cancer Discovery

    Research

    Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

    2025

    Via Cancer

    Research

    Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

    2025

    Via medRxiv

    Research

    A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results

    2025

    Via Cancer Chemotherapy and Pharmacology

    Research

    Clinical and translational study of ivosidenib plus nivolumab in advanced solid tumors harboring IDH1 mutations

    2025

    Via The Oncologist

    Research

    Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)

    2025

    Via Cancer

    Research

    Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma

    2025

    Via medRxiv